The purpose of the assessment is to evaluate the relative effectiveness and safety of noninvasive prenatal testing (NIPT) for the screening of fetal trisomy 21, trisomy 18 and trisomy 13 in comparison to first trimester combined screening, evaluating the potential benefits and risks of the different screening pathways.
The final version of the assessment was published in February 2018. This is a revised version of the report originally posted on February 9th, 2018. An error was identified in the reference list which is now corrected.
Below is the documentation provided by the Collaborative Assessment authoring team:
OTCA03_Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing_V1.5
OTCA03_summarised_comment_external_experts_and_manufacturers_on_2nd_draft_assessment_0
